Wanbang Of China To Develop D-Pharm Anti-Stroke Drug From Phase III
This article was originally published in PharmAsia News
China's Wanbang Biopharmaceuticals, the nation's largest insulin maker, has signed an agreement with Israel's D-Pharm to develop drugs to prevent strokes in China. Wanbang is to begin by covering the cost of the Phase III trials already under way for D-Pharm's DP-b99 membrane active chelator drug. Wanbang also is to pay D-Pharm up to $25.5 million if the drug gets approved, and then will pay royalties. (Click here for more
You may also be interested in...
The US Medicare agency on 7 April said it delivered $34bn to suppliers of durable medical equipment and other providers fighting COVID-19 via an accelerated payment program.
Class Action Watch: Plaintiffs Target L’Oreal’s Pump-Dispensed Liquid Cosmetics, GNC’s Vitamin E Oil
According to a class action complaint filed in California’s Northern District, L’Oreal shortchanges consumers by packaging liquid makeup offerings so that users cannot access significant amounts of product. Meanwhile, the authenticity of GNC’s Vitamin E Skin Oil is being challenged in another California federal court, and Unilever ducks a class action in Texas concerning mercury in Pond’s Rejuveness.
Low-skilled malicious hackers with physical access to certain Becton Dickinson hospital drug dispensers could access sensitive patient data and even alter them, a report from the US Department of Homeland Security says. The company and DHS are advising users to put extra measures in place to mitigate the threat while BD develops a software patch.